Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer

Enzalutamide (MDV3100) is a second generation Androgen Receptor (AR) antagonist with proven efficacy in the treatment of castration resistant prostate cancer (CRPC). The majority of treated patients, however, develop resistance and disease progression and there is a critical need to identify novel t...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Kregel, Steven, Chen, James L., Tom, Westin, Krishnan, Venkatesh, Kach, Jacob, Brechka, Hannah, Fessenden, Tim B., Isikbay, Masis, Paner, Gladell P., Szmulewitz, Russell Z., Vander Griend, Donald J.
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5041979/
https://ncbi.nlm.nih.gov/pubmed/27036029
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.8456
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares